Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential

被引：0

作者：

Lica, Jan Jakub ^{[1
]}

Pradhan, Bhaskar ^{[2
]}

Safi, Kawthar ^{[3
]}

Jakobkiewicz-Banecka, Joanna ^{[4
]}

Hellmann, Andrzej ^{[5
]}

机构：

[1] Powisle Univ, Fac Hlth Sci, PL-80214 Gdansk, Poland

[2] Med Univ Warsaw, Fac Pharm, Dept Biochem, PL-02097 Warsaw, Poland

[3] Med Univ Warsaw, Fac Biol, Dept Biochem & Clin Chem, PL-02097 Warsaw, Poland

[4] Univ Gdansk, Fac Biol, Dept Med Biol & Genet, PL-80308 Gdansk, Poland

[5] Med Univ Gdansk, Fac Med, Dept Hematol & Transplantol, PL-80214 Gdansk, Poland

来源：

MOLECULES | 2024年 / 29卷 / 17期

关键词：

hematologic cancers; innovative approaches; therapeutic modalities; synergistic potential; PI3K inhibitors; proteasome inhibitors; NF-kappa B inhibitors; immunotherapy checkpoint inhibitors; neddylation inhibitors; small molecules; CHECKPOINT BLOCKADE; TARGETED THERAPIES; INHIBITOR; CELLS; TIM-3; ANTIBODIES; RITUXIMAB; HEALTH;

D O I：

10.3390/molecules29174280

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

In this review we explore innovative approaches in the treatment of hematologic cancers by combining various therapeutic modalities. We discuss the synergistic potential of combining inhibitors targeting different cellular pathways with immunotherapies, molecular therapies, and hormonal therapies. Examples include combining PI3K inhibitors with proteasome inhibitors, NF-kappa B inhibitors with immunotherapy checkpoint inhibitors, and neddylation inhibitors with therapies targeting the tumor microenvironment. Additionally, we discuss the potential use of small molecules and peptide inhibitors in hematologic cancer treatment. These multidimensional therapeutic combinations present promising strategies for enhancing treatment efficacy and overcoming resistance mechanisms. However, further clinical research is required to validate their effectiveness and safety profiles in hematologic cancer patients.

引用

下载

页数：40

共 50 条

[21] Identification of novel regulators and therapeutic targets in hematologic malignancies
Post, Sean M.
Gallardo, Miguel
Hornbaker, Marisa J.
Zhang, Xiaorui
Bueso-Ramos, Carlos
Parker-Thornburg, Jan
Hu, Peter
Rapado, Inmaculada
Quintas-Cardama, Alfonso
Komblau, Steven M.
Martinez-Lopez, Joaquin
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 : S53 - S53
[22] The therapeutic impact of streptococci and enterococci in patients with hematologic malignancies
Ombandza-Moussa, E
Schlegel, L
Vekhoff, A
Gerbal, R
Marie, JP
Bouvet, A
PATHOLOGIE BIOLOGIE, 2002, 50 (03): : 169 - 177
[23] Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention
Norde, Wieger J.
Hobo, Willemijn
van der Voort, Robbert
Dolstra, Harry
BLOOD, 2012, 120 (04) : 728 - 736
[24] POTENTIAL APPLICATIONS OF CYTODIFFERENTIATION THERAPY IN HEMATOLOGIC MALIGNANCIES
BREITMAN, TR
CHEN, ZX
TAKAHASHI, N
SEMINARS IN HEMATOLOGY, 1994, 31 (04) : 18 - 25
[25] The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K
Anderson, KC
BLOOD, 2005, 105 (04) : 1383 - 1395
[26] Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy
Fuchs, Ota
CURRENT SIGNAL TRANSDUCTION THERAPY, 2011, 6 (01) : 44 - 54
[27] Epigenetic Aberrations in Cholangiocarcinoma: Potential Biomarkers and Promising Target for Novel Therapeutic Strategies
Limpaiboon, Temduang
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 : 41 - 45
[28] Therapeutic monoclonal antibodies in hematologic malignancies: Biological responses and safety
Rate, R.
Ludwig, W. -D.
ANNALS OF HEMATOLOGY, 2006, 85 : 42 - 46
[29] CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Testa U.
Pelosi E.
Frankel A.
Biomarker Research, 2 (1)
[30] Recent advances and new therapeutic directions for hematologic malignancies - Introduction
Rosen, ST
SEMINARS IN ONCOLOGY, 2000, 27 (06) : 1 - 1

← 1 2 3 4 5 →